Respiratory Disease in the COVID-19 Era
Coronavirus disease 2019 (COVID-19) is a new respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused a global pandemic. COVID-19 patients often develop acute respiratory distress syndrome (ARDS), which involves acute and lethal respirator...
Guardat en:
| Format: | Online |
|---|---|
| Idioma: | anglès |
| Publicat: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Matèries: | |
| Accés en línia: | ONIX_20230714_9783036579160_58 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1869516554735976448 |
|---|---|
| collection | Directory of Open Access Books |
| description | Coronavirus disease 2019 (COVID-19) is a new respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused a global pandemic. COVID-19 patients often develop acute respiratory distress syndrome (ARDS), which involves acute and lethal respiratory failure. In a meta-analysis, the median incidence of ARDS in COVID-19 patients was found to be 35 (2-79)%, while the mortality rate in COVID-19-associated ARDS patients was found to be 39 (12.5-73.1)% (Hasan, et al. Expert Rev Repoir Med. 2020; 14: 1149). As of 12 December 2021, 270,373,764 cases had been confirmed as COVID-19 and 5,321,321 cases had resulted in death, according to the World Health Organization webpage. Various symptoms such as persistent fatigue, myalgia, and insomnia can persist after recovery from COVID-19; these symptoms are called “long COVID-19”. Patients with COVID-19 who survive but develop pulmonary fibrosis may experience persistent dyspnea upon exertion, a decrease in pulmonary function, and/or a radiological abnormal shadow. Antifibrotic drugs including nintedanib and pirfenidone are candidate drugs for the treatment of pulmonary fibrosis due to COVID-19; randomized controlled trials are ongoing. However, there are limited studies about respiratory disease caused by COVID-19. Given the clinical significance of this topic and its impact on clinical practice and public health, Medicina have published a Special Issue entitled “Respiratory Disease in the COVID-19 Era” with the aim of gathering accurate and up-to-date scientific information of this topic. |
| format | Online |
| id | doab-20.500.12854ir-101359 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1013592024-03-31T13:10:30Z Respiratory Disease in the COVID-19 Era Okamoto, Masaki heart rate COVID-19 pulmonary rehabilitation COVID-19 vaccines adult pneumonia risk SARS-CoV-2 Pneumocystis jirovecii pneumonia interstitial pneumonia steroids immunosuppressive drugs spontaneous pneumomediastinum subcutaneous emphysema therapeutic plasma exchange ARDS inflammatory markers survival immunocompromised host Bruton’s tyrosine kinase persistent infection pulmonary paragonimiasis Paragonimus westermani post-COVID-19 condition delayed diagnosis case cluster Bamlanivimab Etesevimab lung ultrasound RT-qPCR HRCT diabetes mellitus computed tomographic severity score immunocompromised coronavirus disease 2019 hydroxychloroquine severe acute respiratory syndrome n/a diaphragm thoracic mobilization respiratory function thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics Coronavirus disease 2019 (COVID-19) is a new respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused a global pandemic. COVID-19 patients often develop acute respiratory distress syndrome (ARDS), which involves acute and lethal respiratory failure. In a meta-analysis, the median incidence of ARDS in COVID-19 patients was found to be 35 (2-79)%, while the mortality rate in COVID-19-associated ARDS patients was found to be 39 (12.5-73.1)% (Hasan, et al. Expert Rev Repoir Med. 2020; 14: 1149). As of 12 December 2021, 270,373,764 cases had been confirmed as COVID-19 and 5,321,321 cases had resulted in death, according to the World Health Organization webpage. Various symptoms such as persistent fatigue, myalgia, and insomnia can persist after recovery from COVID-19; these symptoms are called “long COVID-19”. Patients with COVID-19 who survive but develop pulmonary fibrosis may experience persistent dyspnea upon exertion, a decrease in pulmonary function, and/or a radiological abnormal shadow. Antifibrotic drugs including nintedanib and pirfenidone are candidate drugs for the treatment of pulmonary fibrosis due to COVID-19; randomized controlled trials are ongoing. However, there are limited studies about respiratory disease caused by COVID-19. Given the clinical significance of this topic and its impact on clinical practice and public health, Medicina have published a Special Issue entitled “Respiratory Disease in the COVID-19 Era” with the aim of gathering accurate and up-to-date scientific information of this topic. 2023-07-14T14:26:53Z 2023-07-14T14:26:53Z 2023 book ONIX_20230714_9783036579160_58 9783036579160 9783036579177 https://directory.doabooks.org/handle/20.500.12854/101359 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/7454 https://mdpi.com/books/pdfview/book/7454 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-7917-7 10.3390/books978-3-0365-7917-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036579160 9783036579177 112 Basel open access |
| spellingShingle | heart rate COVID-19 pulmonary rehabilitation COVID-19 vaccines adult pneumonia risk SARS-CoV-2 Pneumocystis jirovecii pneumonia interstitial pneumonia steroids immunosuppressive drugs spontaneous pneumomediastinum subcutaneous emphysema therapeutic plasma exchange ARDS inflammatory markers survival immunocompromised host Bruton’s tyrosine kinase persistent infection pulmonary paragonimiasis Paragonimus westermani post-COVID-19 condition delayed diagnosis case cluster Bamlanivimab Etesevimab lung ultrasound RT-qPCR HRCT diabetes mellitus computed tomographic severity score immunocompromised coronavirus disease 2019 hydroxychloroquine severe acute respiratory syndrome n/a diaphragm thoracic mobilization respiratory function thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics Respiratory Disease in the COVID-19 Era |
| title | Respiratory Disease in the COVID-19 Era |
| title_full | Respiratory Disease in the COVID-19 Era |
| title_fullStr | Respiratory Disease in the COVID-19 Era |
| title_full_unstemmed | Respiratory Disease in the COVID-19 Era |
| title_short | Respiratory Disease in the COVID-19 Era |
| title_sort | respiratory disease in the covid 19 era |
| topic | heart rate COVID-19 pulmonary rehabilitation COVID-19 vaccines adult pneumonia risk SARS-CoV-2 Pneumocystis jirovecii pneumonia interstitial pneumonia steroids immunosuppressive drugs spontaneous pneumomediastinum subcutaneous emphysema therapeutic plasma exchange ARDS inflammatory markers survival immunocompromised host Bruton’s tyrosine kinase persistent infection pulmonary paragonimiasis Paragonimus westermani post-COVID-19 condition delayed diagnosis case cluster Bamlanivimab Etesevimab lung ultrasound RT-qPCR HRCT diabetes mellitus computed tomographic severity score immunocompromised coronavirus disease 2019 hydroxychloroquine severe acute respiratory syndrome n/a diaphragm thoracic mobilization respiratory function thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics |
| topic_facet | heart rate COVID-19 pulmonary rehabilitation COVID-19 vaccines adult pneumonia risk SARS-CoV-2 Pneumocystis jirovecii pneumonia interstitial pneumonia steroids immunosuppressive drugs spontaneous pneumomediastinum subcutaneous emphysema therapeutic plasma exchange ARDS inflammatory markers survival immunocompromised host Bruton’s tyrosine kinase persistent infection pulmonary paragonimiasis Paragonimus westermani post-COVID-19 condition delayed diagnosis case cluster Bamlanivimab Etesevimab lung ultrasound RT-qPCR HRCT diabetes mellitus computed tomographic severity score immunocompromised coronavirus disease 2019 hydroxychloroquine severe acute respiratory syndrome n/a diaphragm thoracic mobilization respiratory function thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics |
| url | ONIX_20230714_9783036579160_58 |